Cargando…
Positive Programmed Cell Death-Ligand 1 Expression Predicts Poor Treatment Outcomes in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Chemoradiotherapy
Background: Programmed cell death-ligand 1 (PD-L1) is present in a subgroup of cancer patients who may be favorable targets for immune checkpoint inhibitor therapies. However, the significance of the PD-L1 expression in esophageal squamous cell carcinoma (ESCC) patients receiving neoadjuvant chemora...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912507/ https://www.ncbi.nlm.nih.gov/pubmed/31684197 http://dx.doi.org/10.3390/jcm8111864 |
_version_ | 1783479472239935488 |
---|---|
author | Huang, Wan-Ting Lu, Hung-I Wang, Yu-Ming Chen, Yen-Hao Lo, Chien-Ming Lin, Wei-Che Lan, Ya-Chun Tseng, Ling-Huei Li, Shau-Hsuan |
author_facet | Huang, Wan-Ting Lu, Hung-I Wang, Yu-Ming Chen, Yen-Hao Lo, Chien-Ming Lin, Wei-Che Lan, Ya-Chun Tseng, Ling-Huei Li, Shau-Hsuan |
author_sort | Huang, Wan-Ting |
collection | PubMed |
description | Background: Programmed cell death-ligand 1 (PD-L1) is present in a subgroup of cancer patients who may be favorable targets for immune checkpoint inhibitor therapies. However, the significance of the PD-L1 expression in esophageal squamous cell carcinoma (ESCC) patients receiving neoadjuvant chemoradiotherapy remains unclear. Methods: By means of PD-L1 immunohistochemistry 22C3 pharmDx assay, we evaluate the PD-L1 expression and its association with clinical outcome in 107 ESCC patients receiving neoadjuvant chemoradiotherapy. Results: Patients with positive PD-L1 expression have significantly lower pathological complete response rates (13% versus 32%; p = 0.036) than those with negative PD-L1 expression. Univariate survival analysis found that positive PD-L1 expression were correlated with poor overall survival (p = 0.004) and inferior disease-free survival (p < 0.001). In a multivariate analysis, positive PD-L1 expression was independently associated with the absence of a pathologically complete response (p = 0.044, hazard ratio: 3.542), worse overall survival (p = 0.006, hazard ratio: 2.017), and inferior disease-free survival (p < 0.001, hazard ratio: 2.516). Conclusions: For patients with ESCC receiving neoadjuvant chemoradiotherapy, positive PD-L1 expression independently predicts the poor chemoradiotherapy response and worse treatment outcome. Thus, our data suggests that PD-L1 may be an influential biomarker for prognostic classification and for immune checkpoint inhibitor therapies in ESCC patients receiving neoadjuvant chemoradiotherapy. |
format | Online Article Text |
id | pubmed-6912507 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69125072020-01-02 Positive Programmed Cell Death-Ligand 1 Expression Predicts Poor Treatment Outcomes in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Chemoradiotherapy Huang, Wan-Ting Lu, Hung-I Wang, Yu-Ming Chen, Yen-Hao Lo, Chien-Ming Lin, Wei-Che Lan, Ya-Chun Tseng, Ling-Huei Li, Shau-Hsuan J Clin Med Article Background: Programmed cell death-ligand 1 (PD-L1) is present in a subgroup of cancer patients who may be favorable targets for immune checkpoint inhibitor therapies. However, the significance of the PD-L1 expression in esophageal squamous cell carcinoma (ESCC) patients receiving neoadjuvant chemoradiotherapy remains unclear. Methods: By means of PD-L1 immunohistochemistry 22C3 pharmDx assay, we evaluate the PD-L1 expression and its association with clinical outcome in 107 ESCC patients receiving neoadjuvant chemoradiotherapy. Results: Patients with positive PD-L1 expression have significantly lower pathological complete response rates (13% versus 32%; p = 0.036) than those with negative PD-L1 expression. Univariate survival analysis found that positive PD-L1 expression were correlated with poor overall survival (p = 0.004) and inferior disease-free survival (p < 0.001). In a multivariate analysis, positive PD-L1 expression was independently associated with the absence of a pathologically complete response (p = 0.044, hazard ratio: 3.542), worse overall survival (p = 0.006, hazard ratio: 2.017), and inferior disease-free survival (p < 0.001, hazard ratio: 2.516). Conclusions: For patients with ESCC receiving neoadjuvant chemoradiotherapy, positive PD-L1 expression independently predicts the poor chemoradiotherapy response and worse treatment outcome. Thus, our data suggests that PD-L1 may be an influential biomarker for prognostic classification and for immune checkpoint inhibitor therapies in ESCC patients receiving neoadjuvant chemoradiotherapy. MDPI 2019-11-03 /pmc/articles/PMC6912507/ /pubmed/31684197 http://dx.doi.org/10.3390/jcm8111864 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Huang, Wan-Ting Lu, Hung-I Wang, Yu-Ming Chen, Yen-Hao Lo, Chien-Ming Lin, Wei-Che Lan, Ya-Chun Tseng, Ling-Huei Li, Shau-Hsuan Positive Programmed Cell Death-Ligand 1 Expression Predicts Poor Treatment Outcomes in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Chemoradiotherapy |
title | Positive Programmed Cell Death-Ligand 1 Expression Predicts Poor Treatment Outcomes in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Chemoradiotherapy |
title_full | Positive Programmed Cell Death-Ligand 1 Expression Predicts Poor Treatment Outcomes in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Chemoradiotherapy |
title_fullStr | Positive Programmed Cell Death-Ligand 1 Expression Predicts Poor Treatment Outcomes in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Chemoradiotherapy |
title_full_unstemmed | Positive Programmed Cell Death-Ligand 1 Expression Predicts Poor Treatment Outcomes in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Chemoradiotherapy |
title_short | Positive Programmed Cell Death-Ligand 1 Expression Predicts Poor Treatment Outcomes in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Chemoradiotherapy |
title_sort | positive programmed cell death-ligand 1 expression predicts poor treatment outcomes in esophageal squamous cell carcinoma patients receiving neoadjuvant chemoradiotherapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912507/ https://www.ncbi.nlm.nih.gov/pubmed/31684197 http://dx.doi.org/10.3390/jcm8111864 |
work_keys_str_mv | AT huangwanting positiveprogrammedcelldeathligand1expressionpredictspoortreatmentoutcomesinesophagealsquamouscellcarcinomapatientsreceivingneoadjuvantchemoradiotherapy AT luhungi positiveprogrammedcelldeathligand1expressionpredictspoortreatmentoutcomesinesophagealsquamouscellcarcinomapatientsreceivingneoadjuvantchemoradiotherapy AT wangyuming positiveprogrammedcelldeathligand1expressionpredictspoortreatmentoutcomesinesophagealsquamouscellcarcinomapatientsreceivingneoadjuvantchemoradiotherapy AT chenyenhao positiveprogrammedcelldeathligand1expressionpredictspoortreatmentoutcomesinesophagealsquamouscellcarcinomapatientsreceivingneoadjuvantchemoradiotherapy AT lochienming positiveprogrammedcelldeathligand1expressionpredictspoortreatmentoutcomesinesophagealsquamouscellcarcinomapatientsreceivingneoadjuvantchemoradiotherapy AT linweiche positiveprogrammedcelldeathligand1expressionpredictspoortreatmentoutcomesinesophagealsquamouscellcarcinomapatientsreceivingneoadjuvantchemoradiotherapy AT lanyachun positiveprogrammedcelldeathligand1expressionpredictspoortreatmentoutcomesinesophagealsquamouscellcarcinomapatientsreceivingneoadjuvantchemoradiotherapy AT tsenglinghuei positiveprogrammedcelldeathligand1expressionpredictspoortreatmentoutcomesinesophagealsquamouscellcarcinomapatientsreceivingneoadjuvantchemoradiotherapy AT lishauhsuan positiveprogrammedcelldeathligand1expressionpredictspoortreatmentoutcomesinesophagealsquamouscellcarcinomapatientsreceivingneoadjuvantchemoradiotherapy |